A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Osteosarcoma Clinical Trial

Official title:

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00752206
• Other study ID #: SARC012
• Secondary ID: D8180C00039
• Status: Terminated
• Phase: Phase 2
• Start date: March 2009
• Est. completion date: December 2017

Study information

• Verified date: April 2019
• Source: Sarcoma Alliance for Research through Collaboration
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).

Description:

Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

After complete surgical removal of their cancer, patients will be randomly assigned to receive either Saracatinib or placebo (a sugar pill) throughout the study. Patients will take Saracatinib (or placebo) once daily by mouth for a total of 364 days. The duration of treatment is divided into 13 cycles, 28 days each cycle with no breaks in between.

Patients will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. To monitor for recurrence of tumor, patients will undergo thoracic CT scans at 3-4 weeks, 6-8 weeks, at 3 months, at 6 months, at 9 months, at 12 months, then every 6 months up to 2 years, and then every year up to 5 years after starting treatment. An electrocardiogram (ECG) will be taken at 3 months, and a bone scan will be performed at 12 months.

Patients who recur in the lung while on-study and who are thought to be amenable to complete surgical resection will be able to find out if they were receiving placebo or saracatinib. Those patients who were receiving placebo may then have the option of undergoing surgical resection. If fully resected of all recurrent disease,they will be given the option of receiving oral therapy with saracatinib. Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be thirteen 28-day cycles (364 days total). If complete resection of all lung nodules is not achieved, the patient will be removed from the study.

Patients who recur in locations other than the lung while on-study will be taken off study at that time.

Blood and tumor samples for research purposes will be collected at the time the tumor is removed.

After completing all 13 cycles, patients will be followed for approximately every 3 months until 2 years from starting treatment, then approximately every 6 months until 4 years from starting treatment, and once at year 5.

Other known NCT identifiers

• NCT00923286

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: December 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 74 Years

Eligibility

Inclusion Criteria:

• Patient had recurrence of osteosarcoma, localized to the lungs, had complete surgical removal of all lung nodules are eligible for enrollment.

• Patient with suspected recurrence of osteosarcoma but who has not had surgery is eligible for enrollment but will not be randomized to receive study medication until deemed fully eligible following surgical removal of all lung nodules.

• Patient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.

• Patient had recurrence of osteosarcoma in the lung following standard therapy including: adriamycin, cisplatin, ifosfamide and methotrexate.

• Patient is = 15 and < 75 years of age.

• Weight = 34 kg.

• ECOG performance score of 0-2.

• Adequate bone marrow function.

• Adequate renal function.

• Adequate hepatic function.

• Adequate cardiac function.

• Women of childbearing potential must have had a negative pregnancy test (urine or serum) = 7 days prior to enrollment, and willingness to use an acceptable method of contraception during participation in the study and for 3 months after the last dose.

• Randomization must occur = 6 weeks after complete surgical resection.

• Patient or legal guardian has signed informed consent.

Exclusion Criteria:

• Presence of metastatic disease in other locations in addition to the lung.

• Disruption of the lung pleura by tumor.

• Paget's disease.

• Patient currently using, or has previously used CYP3A4 inducers or inhibitors within 2 to 14 days prior to the initiation of oral therapy.

• Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.

• Evidence of interstitial lung disease.

• Any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.

• Myocardial infarction within one year prior to study entry.

• Bleeding diathesis, resulting in symptomatic bleeding.

• Patient is pregnant or nursing/breast-feeding.

• Patient received chemotherapy, biological or investigational agent = 28 days prior to enrollment.

• Patient experiencing unresolved toxicity = CTCAE grade 2 (except alopecia) from previous agents.

Related Conditions & MeSH terms

• Osteosarcoma

Intervention

Drug:
• Saracatinib
Oral Agent
• Placebo
Oral Agent

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland
United States	National Cancer Institute	Bethesda	Maryland
United States	University of Alabama	Birmingham	Alabama
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	University of Florida	Gainesville	Florida
United States	Indiana University	Indianapolis	Indiana
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	UCLA/Mattel's Children's Hospital	Los Angeles	California
United States	USC/Norris Comprehensive Cancer Center and Hospital	Los Angeles	California
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	University of Miami	Miami	Florida
United States	Stanford University	Palo Alto	California
United States	UCSF	San Francisco	California
United States	Sarcoma Oncology Center	Santa Monica	California
United States	Seattle Cancer Care Alliance/University of Washington Medical Center	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Sarcoma Alliance for Research through Collaboration	AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival Rate Among Patients Treated With Saracatinib and Placebo.	To determine if the addition of saracatinib to pulmonary metastasectomy, versus placebo and pulmonary metastasectomy, results in a change in progression free survival.	Evaluation for recurrence/progression will be made every 3 months for the 1st year, then every 6 months up to 2 years, then every year up to 5 years after starting treatment.
Secondary	Change in Overall Survival With the Addition of Saracatinib to Pulmonary Metastasectomy, Versus Placebo and Pulmonary Metastasectomy	To determine if the addition of saracatinib to pulmonary metastasectomy, versus placebo and pulmonary metastasectomy, results in a change in overall survival.	5 year overall survival
Secondary	Change in Time to Treatment Failure With the Addition of Saracatinib to Pulmonary Metastasectomy, Versus Placebo and Pulmonary Metastasectomy	To determine if the addition of saracatinib to pulmonary metastasectomy, versus placebo and pulmonary metastasectomy, results in a change in the time to treatment failure. Time to treatment failure is the time from randomization to treatment discontinuation.	Up to 12 months
Secondary	Number of Genes Identified for Prediction of Recurrence of Osteosarcoma	To perform microarray analysis of tumor samples to identify a gene signature that predicts for recurrence of osteosarcoma using methodology that relies on preparation of RNA, followed by cDNA. Fluorescent labeling followed by hybridization to a DNA chip allows for quantitative scanning for hybridized complexes.	Up to 12 months
Secondary	Biomarkers Related to Activation of Src and Src Substrates	To evaluate tumor samples for biomarkers related to activation of Src and Src substrates.	Up to 12 months
Secondary	Cell Lines and Murine Xenografts From Recurrent Tumor Samples	To establish cell lines and murine xenografts from recurrent tumor samples.	Up to 12 months
Secondary	Number of Mutations Identified That May be Causative For Recurrent Osteosarcoma	To perform sequencing analysis of DNA and RNA in tumor samples compared to normal blood to detect mutations that may be causative for recurrent osteosarcoma. The methodology uses transcriptome sequencing, exon re-sequencing and mate-pair end sequencing, allowing us to detect translocations. The availability of matched normal DNA in the blood will allow us to determine which changes are unique to the tumor.	Up to 12 months

External Links

•   Related Info